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ABSTRACT 
VEHICLES FOR THE ABSORPTION OF VITAMIN D IN CYSTIC FIBROSIS: 
COMPARISON OF POWDER VS. OIL 
By Wendy A. Hermes 
 
Background Despite the high prevalence of vitamin D deficiency in cystic fibrosis (CF) 
populations, there is little consensus on the most efficacious vehicle substance for 
vitamin D supplements. Given the high prevalence of pancreatic insufficiency in CF, it is 
possible that resulting fat malabsorption may impede the ability of patients with CF to 
absorb vitamin D in an oil vehicle. Further investigation is needed to determine the 
optimal vehicle substance for use in vitamin D supplements. The objective of this pilot 
study was to compare the absorption of vitamin D3 and to evaluate the rise in serum 
cholecalciferol (D3) concentrations in response to vitamin D supplements contained in 
power or oil vehicles. We hypothesized that vitamin D contained in a powder vehicle 
would be absorbed more efficiently than vitamin D contained in an oil vehicle in patients 
with CF. 
 
Methods: This was a double blind, randomized control trial conducted in adult patients 
with CF during a hospitalization for at least 72 hours at Emory University Hospital for an 
acute CF event. This study was approved by Emory IRB. All subjects gave written 
informed consent for participation. Eligible subjects included adults with CF over the age 
of 18. Subjects were excluded on the basis of a history of hypercalciemia, chronic kidney 
disease (stage 3 or higher), FEV1% <20% or current hepatic dysfunction (total bilirubin 
> 2.5 mg/dL, direct bilirubin > 1.0 mg/dL). Subjects were randomized to either a one-
 
 
time bolus dose of 100,000 IU of vitamin D contained in a powder (BioTech Pharmacal 
Inc., 50,000IU/tablet, inactive ingredients gelatin: lactose, cellulose and magnesium 
stearate) or oil-based vehicle substance (Pro-Pharma, LLC ,10,000 IU/tablet, refined 
soybean oil and glycerin). Serum D3 concentrations were analyzed at baseline, 12, 24, 
and 48 hours post-treatment and serum 25(OH)D3 was measured at baseline, 12, and 24 
hours. Group differences were assessed with repeated measures ANOVA. The area under 
the curve (AUC) for serum D3 and the individual 12-hr time-point were also assessed as 
indicators of D3 absorption in group comparisons (Student’s t-test). 
 
Results: This trial was completed by 16 subjects with CF. The mean age, BMI, and 
FEV1% were 26.2±6.8 yrs., 20.4± 2.4 kg/m2, 63±17%, respectively. The increase in 
serum vitamin D3 concentrations was greater in the powder group (pgroup*time<0.001). 
Serum vitamin D3 was higher at 12-hours in the powder group compared to the oil group 
(144.32± 9.40 vs 80.0± 7.66 ng/dL, p= 0.002), although levels were similar between 
groups by 48 hours.  Plasma 25(OH)D3 concentrations increased significantly (p<0.001), 
although the effect was similar in both groups. 
 
Conclusions: In adults with CF, a large dose of vitamin D3 is more efficiently absorbed 
in a powder vehicle compared to oil by 12 hours after intake. Larger studies are needed to 
determine if the greater acute absorption of vitamin D3 in a powder vehicle translates to 
better health outcomes compared to an oil vehicle. Funded in part by the Cystic Fibrosis 
Foundation. 
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CHAPTER I 
VEHICLES FOR THE ABSORPTION OF VITAMIN D IN CYSTIC FIBROSIS: 
COMPARISON OF POWDER VS. OIL 
 
Introduction 
Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the long arm of 
chromosome 7 in the Cystic Fibrosis Transmembrane Conductance Regulator gene 
(CFTR)1,2. This gene mediates chloride ion secretion and regulates the transport of 
electrolytes across epithelial membranes. Mutations in this gene prevent the chloride 
channel from functioning properly, which impedes the normal flow of chloride ion and 
water into and out of cells. This results in abnormally thick and sticky mucus on the cells 
that line the lungs, pancreas, and other organs. This thickening of the mucus also 
increases the number of lung infections, which leads to damage in the airways and 
decreased lung function. The inflammation from these infections causes progressive 
damage to the epithelial lining of the lungs, which in turn shortens the life span of 
patients suffering from CF3.  
The mutated CFTR gene in the pancreas causes defective secretion of bicarbonate 
leading to pancreatic insufficiency and maldigestion of fat soluble vitamins and chronic 
nutrient deficiencies of vitamin A, E, D, and K. The Delta F508 mutation (a mutation 
causing the deletion of codons for phenylalanine, resulting in defective processing and 
premature breakdown of the CFTR) is the most common, occurring in approximately 80-
2 
 
 
 
90% of patients. Infants are commonly diagnosed with CF shortly after birth with the first 
evidence of pancreatic insufficiency. The  lack of digestive enzyme secretion is caused by 
inhibited exchange of Cl- and K+ ions from CFTR channel proteins, which ultimately 
inhibits endocrine pancreatic juice secretion, blocked ducts and fat malabsorption by the 
gut4,5. Enterically coated pancreatic enzymes are routinely taken at each meal by CF 
patients to enhance uptake of fat soluble vitamins as well to facilitate uptake of minerals 
that compete with fats for absorption.1 
 In 2011, The Cystic Fibrosis Foundation updated recommendations for vitamin D 
therapy in patients with CF, however, due to fat malabsorption problems in CF, there 
remains some question as to the most efficient vehicle compound for the vitamin D 
supplement for maximal absorption.  A vehicle is a substance that may bind or carry the 
vitamin from one place to another and can include fats, water or acidic based substances. 
Vitamin D is a fat soluble vitamin and is more efficiently absorbed when combined with 
a fat/oils as the vehicle compound in healthy individuals and thus most vitamin D pills 
marketed in the U.S. are formulated with a fat soluble vehicle6,7.  However, patients with 
CF are not able to efficiently absorb fats.  Therefore, it is not known whether the vehicle 
substances of vitamin D supplements are poorly absorbed by CF patients. In this study 
we  investigated the effectiveness of absorption of vitamin D in a powder bolus vehicle as 
compared to an oil based vehicle supplement in patients with CF. The hypothesis was 
that a powder based vitamin D3 supplement yields a higher rate of absorption than an oil 
based supplement.
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CHAPTER II 
REVIEW OF THE LITERATURE 
Functions of Vitamin D  
 The role of vitamin D2/D3 in bone health is well documented. Vitamin D2, 
ergosterol, comes from plant sources, whereas vitamin D3, cholecalciferol, is either 
produced in the skin upon contact with UVB radiation and ingestion of oil-rich fish8,9. 
Both forms are available from fortified dairy and cereals.   Vitamin D2 and D3 must first 
be hydroxylated in the liver to 25-hydroxyvitamin D (25(OH)D), and then in the kidneys 
to form 1,25-dihydroxyvitamin D (1,25(OH)2D), to become an active hormone.  
Activation to the biological form in the kidneys requires a hydroxylase enzyme 
(25(OH)D-1-OHase)8. The hormonal form of vitamin D, 1,25(OH)2D, travels to tissues 
with a vitamin D binding protein (DBP)8.  Once it reaches a target tissue, 1,25(OH)2D 
interacts with vitamin D receptors (VDRs). Such receptors are found in multiple tissues 
throughout the body such as small intestines, bones and kidneys9. Vitamin D is thus able 
to serve several well established functions, in addition to its most well-defined roles in 
calcium homeostasis and bone maintenance. New studies present evidence that vitamin D 
plays a role in immunity, genetic transcription and lung health9,10,10–12.  Often studies 
involving vitamin D and immune health have focused on doses higher than the 
recommended intakes for healthy populations13–15.  
4 
 
 
 
The Institute of Medicine has currently set recommended daily intakes (RDI) for vitamin 
D at 600 IU/day in ages 1-70 and 800 IU/day for >70 years, not to exceed 4000 IU as the 
Upper Limit (UL)16.  In the last 10 years several studies have explored doses exceeding 
the UL in relation to vitamin D in its relation to hormonal function and immune 
health6,13,17. Outcomes used to assess this relationship include FEV 1, LL-
37/cathelicidin13,14,18.  A 2011 review on vitamin D and lung health cited studies relating 
higher doses of vitamin D with enhanced FEV1 using cross-sectional NHANES III data 
in non-CF populations9,19. FEV1 is also used as a measure of respiratory function related 
to pathogen growth in the patients with CF, tuberculosis, asthma, and other respiratory 
diseases14,20,21. Studies have illustrated the role of vitamin D in the induction of the 
antimicrobial peptide, cathelicidin (LL-37), exhibiting the body’s initial defense against 
airway pathogens such as Gram-positive, Gram-negative bacteria, fungi, and viruses18.  
Active 1,25(OH)2D is necessary to bind to the nuclear receptor, VDR, to increase mRNA 
expression of cathelicidin in both healthy and compromised lungs.9,18  Associations 
between vitamin D status to the positive genetic expression of at least 160 pathways 
which ultimately may affect outcomes in autoimmune disorders, cancers, and 
cardiovascular disease have been promising22.  A randomized clinical trial by Hossein et 
al in 2013 was important in defining functions of vitamin D3 that have been previously 
elusive, making the deficiency in this vitamin a prime concern for certain populations 
affected by genetic immunity disorders 
5 
 
 
 
Vitamin D Deficiency in Non-CF Populations 
 In 2011 The Endocrine Society updated guidelines for vitamin D supplements and 
treatments in the general population8. These updates occurred in light of vitamin D 
deficiencies within the general population, indicating an increased public health risk.1,8 
An NHANES analysis for the years 1988–1994 and 2000–2006, examined 
hypovitaminosis D within the general population while adjusting for updated assay drifts 
over time, reiterating a general vitamin deficiency while validating assay testing. This 
study emphasizes that higher prevalence of hypovitaminosis D in 2001–2006 compared 
to 1988–1994, with an increase  of 5-10% in all people with serum 25(OH)D <30 ng/ml 
(3 to 8% in men, from 22 to 38% in blacks, from 3 to 8% in 12- to 15-y-old adolescents, 
from 5 to 12% in 20- to 30-y-old adults, from 6 to 14% in non-supplement users, and 
from 8 to 17% in persons with BMI >80th percentile).19 The established deficiency rate 
for all populations was previously described by Holick et al. in 2011 as 25(OH)D < 20 
ng/ml (50 nmol/liter), and insufficient as 25(OH)D of 21–29 ng/ml (525–725 nmol/liter).8 
In response to a vitamin D deficiency within the general population, in the 2012, the CF 
Foundation also updated its guidelines for vitamin D supplements and treatments in 
populations diagnosed with CF.1 
Prevalence of Deficiency in CF Populations 
The prevalence of vitamin D deficiency in CF has been well described from birth 
through adulthood1.  Vitamin D status begins to decline during adolescence and some 
study centers report insufficiency between 81 and 90% by adulthood15,23,24.  Decreased 
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bone mineral density in adulthood may be described by a high frequency of early 
diagnosis of vitamin D deficiency in CF youth25. 
Production of vitamin D in the skin upon exposure to sunlight is one of the 
primary sources of vitamin D in the human body.  While the majority of healthy 
populations get 95% of vitamin D from sunlight, exposure to sunlight is reduced in CF.  
Individuals with CF  have frequent infections requiring hospitalization and are often 
prescribed antibiotics causing increased photosensitivity which further limits exposure to 
sunlight26.  Antibiotic regimens containing chlorines or floroquinolones commonly cause 
UV induced skin rashes, thus  making the use of sunscreens a necessity while reducing 
vitamin D producing capacity in the skin, 27–29.  Therefore, skin formation of vitamin D in 
individuals with CF is reduced compared to individuals without CF and may be one of 
the primary reason for decreased vitamin D status1,30.  Sun exposure is further reduced in 
higher latitudes (47 degrees latitude) posing additional risk for deficiency due to 
decreased UVB penetrating the earth’s surface for cutaneous vitamin D production31.  
Malabsorption of fat soluble vitamins due to pancreatic insufficiency is perhaps 
the most significant barrier for nutrient absorption in CF.  Pancreatic scarring and fibrosis 
causes blockage of digestive enzyme secretion, limiting the absorption of fat soluble 
vitamins2.  Even in the presence of enzymes, research has revealed a reduced level of 
vitamin D absorption in CF. Lark et al. demonstrated that patients with CF only absorbed 
approximately half of the amount of vitamin D administered compared to healthy 
controls32.  
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 Although malabsorption and low sun exposure are primary contributors to vitamin 
D deficiency in CF, more than 20 studies highlight other possible reasons for low vitamin 
D metabolism29.  Inadequate intake of vitamin D fortified foods and supplements, in 
addition to pancreatic exocrine function, limits vitamin D bioavailability25,33.  Impaired 
hepatic hydroxylation, accelerated excretion of vitamin D and decreased expression of 
vitamin D binding protein (VDP) may also contribute to deficiencies29,32,34. 
Implications of Vitamin D Deficiency in CF 
  The role of vitamin D in skeletal health in the general population and CF is well 
established.  Several CF centers have established vitamin D deficiency as a risk factor for 
low bone mineral density in patients with CF and cite preventative supplementation11,35–
38. However, despite the strong association linking vitamin D and skeletal health, there 
have been few random-controlled trials (RCT) proving that low BMD is a direct outcome 
of a vitamin D deficiency39.  A 2010 Cochrane Review outlined only 2 RCTs (Popescu 
data only,1998 and Haworth, 2004) illustrating a BMD outcome after a vitamin D 
supplement with placebo39–41.  Due to its inextricable role in calcium and parathyroid 
hormone homeostasis and (bone remodeling), it is difficult to either exclude or definitely 
prove vitamin D’s true magnitude in bone density.  The current association between CF, 
vitamin D, and skeletal health has primarily been studied through retrospective and cross-
sectional studies assessing BMD directly while also looking at vitamin D deficiencies in 
the samples24,42.  For example, half of the subjects in Elkin et al. had a mean serum 
25(OH)D concentration of 11 ng/mL and 36% of subjects having a serum 25(OH)D < 10 
ng/mL.  From this population, 27% also had at least one vertebral fracture and 11% had 
two vertebral fractures over a 2-year period42.  This study demonstrated an association 
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between low serum 25(OH)D and the increased risk for fracture, but does not clearly 
prove the cause of these bone density related fractures.  
 Lung function and the ability to fight infection are both important in the CF 
population as a predictor of morbidity and mortality14,43.  Decreased serum 25(OH)D is 
associated with decreased lung function as measured by Forced Expiratory Volume in 
one second (FEV1), as well as a higher frequency of bacterial colonization from bacteria 
such as P. aeruginosa44. Low vitamin D status is associated with an increased number of 
hospital stays and ultimately increased mortality in CF1,14,29.  One cross-sectional study 
examined incidence of the first P. aeruginosa infection and percent predicted lung 
function in children aged 8, 12, and 16 years.  The study concluded that higher serum 
25(OH)D levels in children with CF were associated with fewer pulmonary 
exacerbations, and in adolescents, higher FEV143.  This result supported conclusions 
previously demonstrating an association between vitamin D status and  lung function  in 
non-CF populations20. 
 Vitamin D status may also play a role in CFRD.  Diabetes develops in up to 25% 
of young adults, and up to 50% in later adulthood45.  Research in the non-CF population 
suggests that vitamin D may have a positive effect on insulin sensitivity in that it may 
help lower serum glucose and mediate insulin sensitivity46–49.  However, more random 
controlled trials are needed in the CF population to more clearly define this role.  One 
RCT in CF, Pincikova et al., studied CF patients from Sweden, Norway and Denmark 
and demonstrated a positive association between glycosylated hemoglobin (HbA1C) and 
vitamin D insufficiency suggesting a link between vitamin D deficiency and pancreatic 
endocrine insufficiency in CF50.  Pincikova et al suggests that vitamin D supplementation 
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improves insulin secretion and sensitivity by reducing inflammation. Inflammatory 
markers such as C-reactive protein, IL-1, IL-6 and TNF-alpha are elevated in CFRD as 
well as insulin resistance, type 2 diabetes46. 
 Vitamin D and inflammation are strongly associated with CF infections.  A 2011 
study of CF respiratory epithelial cell lines exposed to Pseudomonas aeruginosa found a 
decrease in inflammatory cytokines IL-6 and IL-8  when exposed to  the hormonal form 
of vitamin D, 1,25(OH)2D51.  Vitamin D may up-regulate anti-microbial peptides, 
namely cathelicidin, to enhance clearance of bacteria at various barrier sites and in 
immune cells52,53.  A 2009 review examined literature regarding clinical evidence for 
vitamin D as a modulator of the innate and adaptive immune system53.  Cathelicidin 
exhibits a bacterial killing response in humans and is expressed by epithelial cells of 
respiratory tract.  In people with reduced cathelicidin, bacteria accumulation increases 
inflammatory responses53.  A randomized placebo-controlled trial in adults with CF 
comparing vitamin D vs placebo found a statistically significant 50.4% reduction in 
tumor necrosis factor-α (TNF-α) and a trend for a reduction in IL-6 in CF patients given a 
bolus dose of 250,000 IU of vitamin D314.  Therefore, vitamin D may have multiple 
effects on innate immunity by increasing anti-microbial peptides and by mediating 
inflammation.  
 While there has yet to be a definitive recommendation for vitamin D formulation, 
there have been studies using both vitamin D2 and D3 13–15,17. There have been mixed 
results on the effective absorption of vitamin D2 in CF populations, however, vehicles 
used in clinical studies were primarily oil based (comprised of refined soybean oil and 
glycerin)1,8,32,54,55.  Conversely, clinical trials supplementing vitamin D3 have mainly 
10 
 
 
 
employed the use of a powder vehicle (comprised of lactose, cellulose and magnesium 
stearate)6. The Endocrine and Cystic Fibrosis Society now recommend the use of vitamin 
D3 for supplement use1,8. This recommendation is based on results indicating that 
cholecalciferol (D3) may exhibit greater pharmacokinetic potency than ergocalciferol 
(D2), and as such will be better absorbed in CF than D2.  Green et al 2008 and Rovner et 
al 2007 (respectively) both describe high dose vitamin D studies in children and adults 
with CF, finding that vitamin D2 did not maintain serum 25(OH)D at sufficient levels25,56.  
Conversely, a single randomized trial directly compared side by side an oil vehicle of D2, 
a lactose based vehicle of D3, and cholecalciferol production by UVB in CF patients. 
While this trial found both D2 and D3 adequate in raising serum 25(OH)D to sufficient 
levels (>30 ng/mL), the results were confounded by the difference in the vehicle of 
absorption54. Only one study compared vitamin D2 and D3 side by side in healthy 
populations with 25,000 IU of vitamin D in whole milk compared to the same dose in oil 
on toast57. The authors then performed a study to demonstrate that vitamin D fortified 
orange juice (D3) could be used to successfully raise vitamin D status in healthy 
individuals17.  We propose that the vehicle may be the reason for differences in 
absorption of vitamin D2 and D3 in CF patients.  Given that fat contents are malabsorbed 
in CF, we hypothesized that an oil form of vitamin D3 will be less effectively absorbed 
than a powder bolus vehicle in CF patients. 
This proposal hopes to close a gap in vitamin D guidelines for the CF population. 
The CF Foundation has been unable to update recommendations on the vehicle (i.e. 
substance compound of the vitamin D supplement) for vitamin D supplements  due to 
insufficient studies1.  A comprehensive 2010 review of vitamin D vehicle trials identified 
11 
 
 
 
and compared four studies for this purpose, comparing oil, cellulose/lactose, and ethanol 
as absorption mechanisms, in healthy subjects6. In this literature review concerning non-
CF subjects, oil was concluded as the most efficacious vehicle, however the studies using 
oil were only partially verified and had confounding variables6,58–61.  There have been no 
clinical trials conducted in the CF population to evaluate the impact of the vehicle 
substance on absorption of vitamin D.  This lack of evidence indicates a need for clear 
delineation in the CF population for either a oil or powder vehicle.  
The objective of this study is to combine current resulting factors of digestion, 
absorption and pharmacokinetics of vitamin D in determining the most effective vehicle 
for CF patients. Based on the current understanding that fat is malabsorbed in CF, 
the hypothesis is that a powder mechanism will support better overall absorption in 
this population. Determination of such a pathway would be valuable in the future 
treatment not only in CF, but of other vulnerable populations with increased risk for 
malabsorption disorders6.
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CHAPTER III 
METHODS AND PROCEDURES 
 We proposed a randomized double-blind clinical trial of approximately 12-24 CF 
subjects (>18 yrs. old) to be recruited at Emory (Emory University Hospital ) to compare 
the absorptive efficacy of an oral powder vehicle or oil vehicle containing a total of 
vitamin D3 (100,000 IU) supplement. Baseline studies were conducted upon hospital 
admission and informed consent. Urine was collected prior to enrollment to perform a 
pregnancy test in all females of child-bearing potential if was not already been performed 
as part of standard of care procedures. During a 3-4 day hospitalization, subjects were 
randomly assigned to one of two groups. Group 1 received a powder vitamin D3 bolus 
and Group 2 received an oil supplement of 100,000 IU vitamin D3 each. Information was 
extracted from the medical record and from questions to the participant to assess current 
vitamin supplementations, enzyme use and current overall health concerning CF. Serial 
samples for blood markers for vitamin D3 status (serum vitamin D3 and 
plasma25(OH)D). 
Clinical data were abstracted from electronic medical health records. Clinical data 
collected included age, gender, ethnicity, BMI, genotype, co-morbidities such as kidney 
or liver disease, antibiotic use, HbA1C, most recent plasma 25 hydroxyvitamin D3 
[25(OH)D], and FEV% in 1 second as a measure of lung function. Questionnaires for 
research purposes were given to participants after enrollment to collect data for recent 
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sun exposure, smoking status/packs per day, alcohol consumption, current vitamin D 
supplementation and enzyme use.  
 Recruitment was performed through referral from the Emory University Hospital 
service caring for CF patients and the outpatient CF Clinics.  At Emory, referrals were 
received from the Emory University Hospital Clinic. Screening of new inpatients was 
completed daily by a research coordinator. Patients who met the following inclusion 
criteria and met none of the exclusion criteria on the initial assessment were offered the 
opportunity to participate in the study.  The study coordinator explained the study 
protocol in detail in the consent form as well as verbally to prospective participants.   
Intervention 
 Patients were randomly assigned to a powder supplement or to an oil based 
supplement each of 100,000 IU vitamin D3. Patients were randomized following 
recruitment in blocks of 4 (meaning for every 4 subjects there will be 2 powder treated 
patients and 2 oil treated patients).  Blood was drawn by IV catheter at baseline, 2, 4, 8, 
12, 24, 48, and 72 hours after vitamin D3 dosing. The powder bolus, Vitamin D3-50 
Cholecalciferol, was obtained from BioTech Pharmacal Inc. (50,000IU/tablet, inactive 
ingredients gelatin: lactose, cellulose and magnesium stearate). The cholecalciferol oil-
based supplements were obtained from Pro-Pharma, LLC (Maximum D3, 
10,000IU/tablet, refined soybean oil and glycerin). A Certificate of Analysis was 
obtained from Analytical Research Laboratories (ARL; 840 RESEARCH PARKWAY, 
SUITE 546 OKLAHOMA CITY, OK 73104) to validate capsule content potency of both 
the powder and the oil D3 capsules.  The 50,000IU powder capsule was found to contain 
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91.3% of the stated amount of vitamin D and the oil capsule was found to contain 95% of 
the stated amount of vitamin D. 
Follow-up 
 Patients received a validated 3-day food diary to complete after release from the 
hospital and to return at a later date. The food diary was used to assess a habitual intake 
of vitamin D per subject to account for variations of vitamin D3 found in blood due to 
intake. Follow-up phone calls were made to ensure compliance for the food diary.  
Questionnaires were used as validation measures for relating blood levels of vitamin D3 
after dosing. 
Inclusion Criteria 
Adult CF patients (>18 yrs), Able to tolerate oral medication, Expected to survive the 
duration of the study. 
Exclusion Criteria 
Inability to obtain or declined informed consent from the subject and/or legally 
authorized representative; a history of disorders associated with hypercalcemia and/or 
current hypercalcemia (albumin-corrected, serum calcium >10.8 mg/dL or ionized 
calcium >5.2 mg/dL), Chronic kidney disease worse than stage III (<60 ml/min), FEV1% 
predicted <20%, Current significant hepatic dysfunction total bilirubin > 2.5 mg/dL with 
direct bilirubin > 1.0 mg/dL, Current use of cytotoxic or immunosuppressive drugs; 
History of AIDS or illicit drug abuse; too ill to participate in study based on 
investigator’s or study team’s opinion; current enrollment in another intervention trial. 
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Biochemical Analysis 
 Serum cholecalciferol at times 0, 12, 24, 48, and 72 was measured with LC-
MS/MS at Heartland Assays, Ames, IA. Peak absorption of cholecalciferol was assessed 
using the 12-hr time point, based on two preceding published recommendations by Lo et 
al and Farraye et al62,63. The area under the curve (AUC) for serum cholecalciferol over 
all time points, calculated using the trapezoidal method64, was also assessed as an 
indicator of absorption. A higher 12 hour serum cholecalciferol or higher AUC reflects 
greater cholecalciferol absorption.  Plasma 25(OH)D and PTH were measured with 
automated chemiluminescence assay (iSYS System, Immunodiagnostic Systems Inc., 
Gaithersurg, MD, USA). External quality assessment is monitored annually through the 
vitamin D external quality assessment scheme (DEQAS) certification. This measure 
ensures that 75% or more of the 'useable' results (generally 16) should fall within ± 25% 
of the Target Value65. To minimize interassay variability, all samples were analyzed 
simultaneously.  
Statistical Analysis and Power 
 Descriptive statistics were performed and reported as mean ± SD or n (%). 
Vehicle (oil vs powder) group differences in baseline demographics were analyzed with 
Fischer’s Exact tests for categorical variables and student’s t-tests for continuous 
variables. Student’s t-tests were used to examine vehicle group differences in the AUC 
for serum cholecalciferol over 48 hours and at the individual 12-hour time point. Two-
way mixed model repeated measures ANOVA was used to test for differences in serum 
cholecalciferol and 25(OH)D by group, over time, and in the group by time interactions. 
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Post-hoc treatment and individual time responses were analyzed using  Tukey’s T-tests 
(p<0.05). Statistical analyses were performed with JMP Pro ™ 10.0.0 (SAS institute Inc., 
Cary, NC) using two-sided tests and assuming a 5% significance level. As this is a novel 
pilot study and there are no previously published trials from which to draw power 
calculations, a formal power analysis was not conducted. We aimed to recruit 12-24 
subjects to establish feasibility and produce needed preliminary data for a future, 
adequately powered, robust clinical trial. 
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CHAPTER IV 
RESULTS 
Subject Demographics 
 A CONSORT diagram of study enrollment is provided in Figure 2. A total of 17 
participants were randomized to receive 100,000 IUs of cholecalciferol in either oil or a powder 
form (Figure 1). Results of the study are reported only for participants who completed at least 0, 
12, and 24 hour time points (n=6 in powder group, n=9 in oil group). One participant withdrew 
from the study prior to completing all crucial time points and was therefore excluded from final 
analysis. A second participant was excluded from final analysis for an inability to acquire an 
adequate blood sample at the 12-hr time point. 
 Baseline demographic and clinical characteristics are presented in Table 1.  The 
demographics for each group are approximately evenly distributed with no significant differences 
between oil or powder as the cholecalciferol vehicle.  The mean age of the group was 26.2±6.8 
years, approximately 50% were female and 88% were of Caucasian ethnicity. One participant 
was of African American decent and one of East Asian descent. The mean BMI was 
approximately 20 kg/m2.  Only two participants were not on a pancreatic enzyme regimen, and 
29% were currently prescribed a vitamin D supplement. CF related diabetes status and insulin 
resistance was noted from patient medical charts. Patients were rated as having normal blood 
glucose, impaired fasting glucose, impaired glucose tolerance, CFRD with fasting hyperglycemia, 
CFRD without fasting hyperglycemia, or unknown. A diagnosis of CFRD and insulin resistance 
was obtained on the basis of A1C% (n=13) and oral glucose tolerance testing (2).  Four subjects 
met one of the above criteria; two had impaired fasting glucose, one had impaired glucose 
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tolerance, three had CFRD with fasting hyperglycemia and three were of unknown status as of 
their last physical exam. Most participants (75%, n=12) had recent serum 25-hydroxyvitamin D 
levels below CF sufficiency recommendations (30 ng/mL); three (25%) in the insufficient (20-30 
ng/mL) and eight (66%) in the deficiency ranges (<20 ng/mL). The mean FEV % in 1 second was 
49.1% 
Changes in Serum Cholecalciferol Over time 
  Serum Cholecalciferol measurements for the powder group at baseline, 12, 24, 
and 48 hours were 4.62 ± 9.40. As shown in Table 2 (Figure 3), there was a statistically 
significant time effect (repeated measures ANOVA Ptime <0.0001) indicating that serum 
cholecalciferol increased over 48hrs in both the oil and the powder groups. The group-by-
time interaction was statistically significant (Pgroup*time<0.0001), reflecting a higher serum 
cholecalciferol response in the powder group (Figure 2). Serum cholecalciferol was 
higher at 12-hrs in the powder group compared to the oil group (144.32± 9.40 vs 80.0± 
7.66 ng/dL, P = 0.002). The powder group increased by an average of 140 ng/ from 
baseline to a peak at the 12 hour time point, whereas the oil group increased an average 
74 ng/ml by 12 hours. The D3 in the oil group following the 12 hour time point continued 
to climb another 15% to reach its peak at 93.7 ng/dL before descending back to 60 ng/dL 
by 48 hours (p<.05).  The powder group had a mean decrease of 74% from the 12 to 24 
hour point (37 ng/dL) and an additional 32% from 24 to 48 hrs (50 ng/dL). All changes 
between time points 12 to 48 were statistically significant (p<.05) with the exception of 
points between 12 and 24 hours in the oil group. Powder and oil serum cholecalciferol 
were equal by the 48 hour time pint with 60.2 and 60.0 ng/dL respectively. The AUC for 
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serum cholecalciferol (Figure 4) was also higher in the powder group compared to the oil 
group (3256.5±285.5 vs 2393.73±233.1, p = 0.036).  
Plasma 25-hydroxyvitamin D by time and group  
  Two-way repeated measures ANOVA analyses (Table 3, Figure 5) indicated that serum 
25-hydroxyvitamin D (25(OH)D) increased significantly by time (ptime=0.006), although 
the group effect and the group by time interaction were not different (pgroup = 0.347, 
pgroup*time = 0.300). Serum 25-hydroxyvitamin D increased from levels considered 
deficient (<20 ng/mL) meet the recommended range for vitamin D sufficiency at (>30 
ng/mL) within 24 hours in the powder group. 
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CHAPTER V 
DISCUSSION 
 This pilot study examined differences of absorption of two opposing vehicles of a 
vitamin D3 supplement in people with Cystic Fibrosis. Cystic Fibrosis is a genetic 
disorder affecting the exocrine function of the pancreas through scarring and limited 
release of digestive enzymes into the small intestine. Pancreatic enzymes and bile are the 
primary mechanism for the absorption of fats and fat soluble vitamins; thus in CF, these 
are markedly decreased. In non-CF groups dietary intake is absorbed most efficiently in 
foods containing fats.  A 2014 randomized control trial compared plasma D3 in healthy 
adults after a 30% fat meal compared to a fat-free meal, finding that subjects consuming 
the fat containing meal absorbed 32% more of a 50,000 IU vitamin D supplement than 
the fat free group (P=0.003)7. 
  Pancreatic scarring in CF decreases available enzymes that aid absorption. 
Although pancreatic enzymes replace this deficit, people with CF still exhibit 
malabsorption compared to their non-CF counterparts when consuming vitamin D with 
oils54. We proposed that a supplement prepared in a water soluble powder vehicle 
(powder composed of lactose, cellulose and magnesium stearate) would be more freely 
absorbed than an oil preparation (refined soybean oil and glycerin) in CF since absorption 
of water soluble vitamins does not require micellar packaging or lipase enzymes. Other 
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common CF fat soluble vitamins already are routinely prepared within a water soluble 
format such as lactose, cellulose and/or magnesium stearate66. 
 This study found a significant rise in serum cholecalciferol from a powder 
compared to an oil vehicle after a bolus dose of 100,000 IU vitamin D3 in CF patients 
(p<0.05). At baseline, 11 study subjects exhibited cholecalciferol levels of five ng/dL or 
less.  Four subjects had levels less than 10 ng/dL, and one subject had a level of 22.5 
ng/dL. We found the peak absorption in powder to occur at approximately 12 hours and 
in oil to be approximately 24 hours. This is consistent with two studies that both 
examined vitamin D absorption in people with intestinal malabsorption compared to 
healthy controls. Lo et al. 1985 developed an oral challenge test to quantifying the 
difference in absorption between healthy controls and patients with fat malabsorption 
syndromes using a 50,000 IU bolus dose of D2,  and found that serum cholecalciferol 
(ng/dL) began to rise four hours after ingestion and 25- hydroxyvitamin D began to rise 
12 hours after ingestion.63 Farraye et al. 2011 further demonstrated a 12 hour peak by 
vitamin D supplementation in patients with Crohn’s disease. Additionally, this clinical 
trial was able to show that anatomical location of malabsorption did not affect absorption 
of vitamin D62. The present study is consistent with this data insofar as cholecalciferol at 
baseline was 7 ng/dL or less for all subjects and was significantly increased by 12 hrs. in 
powder. We found no significant difference between subject groups at baseline. 
 Following peak absorption, both the powder and the oil group had similar vitamin 
D3 levels by 48 hrs. post dose. There was a similar significant rise of serum 25(OH)D in 
both groups from baseline and the powder group had a higher trend toward the 
sufficiency range than the oil group at peak (29, 22.9 ng/mL respectively); however, the 
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difference between the groups was not significant (p=0.347). Previous research 
hypotheses indicate that powder may be more bioavailable in patients with malabsorptive 
disorders6,54. This is the first trial to do a direct comparison of D3 with powder and oil in 
CF.  Khazai et al. 2009 found  that 25(OH)D increased significantly via a powder bolus 
of D3 compared to D2 in oil54.  While this study was longer in duration than the present 
study and also compared different vitamin D compounds (D2 vs D3), the trend of our 
results are consistent with this hypothesis/result. Since this publication, the CF 
Foundation has advocated for the use of D3 in CF based on its confirmed effectiveness in 
raising 25-hydroxyvitamin D over Vitamin D21.  The results in the vitamin D metabolite, 
25(OH)D, do not show a similar parallel rise in the powder group. Since it is 
hypothesized that conversion of cholecalciferol to 25(OH)D is dependent on circulating 
levels of cholecalciferol, we expected a more significant hepatic effect in the powder 
group62. 
  Serum cholecalciferol represents the direct absorption of vitamin D from the 
digestive track and excludes that of the skin. Our result indicated that cholecalciferol 
appropriately measures absorption, yet its overall effectiveness in promoting vitamin D 
status in CF is still unclear. One possible reason for this difference may be the time factor 
in the pilot design of our trial. Khazai et al. 2009 examined 50,000 IU over 12 weeks as 
compared to a one time bolus dose of 100,000 IU evaluated over a 48 hour period. It is 
possible that while this dose was enough to show absorption differences in D3, it was still 
not enough to compare a difference in total vitamin D status. Conversely, the Khazai trial 
found differences that may have been solely related to the vitamin D compound (D2 vs 
D3). Based on our data alone, it is difficult to extrapolate the reason for the difference in 
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rate of hydroxylation of the powder form of D3 to 25(OH)D compared to the oil, whether 
the difference is related to factors associated with CF. Although this trial exhibited that a 
cellulose powder was more effectively absorbed into blood, clinical practice guidelines 
indicate  total 25-hydroxyvitamin D to be a better indicator for overall vitamin D status 
and a clinical marker of health23,67,8.  Additional studies utilizing longer follow-up 
periods may reflect how absorption of cholecalciferol may impact the pathway of hepatic 
25(OH)D. 
 There are several hypothesis to describe possible reasons for reduced levels of 
25(OH)D in the CF population. After ingestion, cholecalciferol is hydroxylated in the 
liver by hepatic 25-alpha hydroxylase enzyme. There is still limited evidence detailing 
the genetic expression of this hepatic enzyme. Zhu et al 2013 has isolated CYP2R1 and a 
second unknown enzyme as the genetic SNP (single-nucleotide polymorphism) for 
hepatic 25-alpha hydroxylase by using double-knockout mice68.  Additionally, Engelman 
et al 2013 also found that a higher dietary exposure of vitamin D was strongly related to 
SNP expression of CYP2R1, suggesting a possible nutrigenomic effect on enzyme 
expression and thus potential 25(OH)D levels69. A second hypothesis describing low 
25(OH)D levels is that sequestration of vitamin D in lipid cells. Due to its fat soluble 
nature vitamin D may be stored in fat cells within either visceral, subcutaneous or 
intramuscular lipid cells, however, research has been inconclusive due to the variability 
of study designs on subjects employed70–72.  People with CF often have low body weight 
independent of body fat, however, since body fatness is not typically measured as part of 
the CF standard of care, we cannot yet hypothesize how vitamin D status is affected by 
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body fat in CF. Additional studies evaluating the relationship between lipid storage and 
muscle mass in both the general population and CF are needed. 
Strengths and Limitations 
 This clinical trial had several limitations. The study was limited in its ability to 
assess long-term vitamin D status in a CF population since samples were collected only 
up to the first 72 hours after dosing.  Collection points for 25(OH)D after 24 hours were 
reduced in power due to subject hospital discharge. Therefore, while we did find a 
significant difference in absorption between the two vehicles in the serum cholecalciferol, 
questions related the secondary clinical outcome with the use of a powder vehicle dosing 
are still unclear. Our primary objective in this pilot study, however, was to measure short-
term absorption to determine vehicle efficacy.  
 The small sample size prevented covariate analysis of any baseline variables to 
the primary study outcome. Baseline characteristic were uniformly distributed between 
groups at enrollment and randomization, however, there were two male subjects excluded 
from final analysis due to inadequate numbers of sample obtained during the 
intervention. The final analysis for each group was n=6 powder and n=9 oil and 62.5 and 
33.3% female respectively. Although this gender difference is not statistically significant, 
the sample size prevents an accurate representation of a more robustly powdered trial. 
Gender is not a determinant in absorption in healthy subjects73 and it has not previously 
been indicated that gender is a determinant of nutrient absorption in CF1. Furthermore, 
there are no gender differences in the prevalence or incidence of CF currently known. 
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Larger trials that examine gender differences in absorption of vitamin D in powder are 
required to determine if this association exists in the general CF population. 
 Finally, the sample in the present study represents a small portion of the CF 
population; recruited as a consequence of their admittance to EUH for an acute CF event. 
At the time of enrollment, the overall health status of study subjects was considered 
“poor health”, and thus, may not be representative of the absorption occurring in a 
healthy person with CF. Although Cystic Fibrosis can be considered a disease of chronic 
inflammation, it is unknown the extent to which CF acute illness has on metabolic 
processes such as nutrient absorption. Trials that compare healthy people with CF and 
those with an acute lung infection will further explain this difference.  
 Strengths of this study are the randomized control design.  Furthermore, this is the 
first trial to measure a direct comparison on two vehicles of cholecalciferol in an adult CF 
population. The CF population is approximately 30,000 individuals with 1/3200 new 
diagnoses each year. This is a relatively small population and as such the sample size of 
the present study was both adequate and feasible given available resources for 
recruitment and time. Furthermore, a significant effect was achieved in the powder group 
which had three fewer subjects on final analysis than the opposing oil group. A larger 
trial of similar design and structure would most likely magnify this result. 
Clinical Significance and Conclusions 
 In this randomized pilot trial we provided a 100,000 IU bolus dose of vitamin D3 
to 17 subjects with Cystic Fibrosis in either a powder or an oil vehicle to evaluate 
absorption efficacy. This is the first clinical trial to evaluate such a direct vehicle 
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mechanism of vitamin D3 absorption. Although the powder mechanism was found to 
significantly increase D3 absorption, reaching a peak at 12 hour post ingestion, both the 
powder and the oil groups had a similar rise in the clinical metabolite of vitamin D 
(25(OH)D). We found no baseline differences in nutritional status nor habitual intake of 
vitamin D foods to be an influence on either absorption or hydroxylase activity in this 
particular trial, however, a closer look at variables describing body composition and 
nutrigenetic effects of foods in a CF population would give a more detailed picture of 
metabolic pathways in vitamin D metabolism and overall health status. 
 We observed a significant rise in 25(OH)D from baseline in both groups, 
indicating the overall effectiveness of D3 in bringing patients with CF in sufficiency 
range.  However, extended follow-up studies are required to evaluate long term health 
effects. 
 Some of the above questions may be addressed in the future by attempting a 
closer evaluation of in vitro muscular lipid metabolism in CF, taking into account the 
possible effects of CFTR mutations on transcription of the hepatic hydroxylation enzyme, 
25-alphahydroxylase. This study did not collect the specific CFTR mutation type for each 
subject, yet several new mutation specific treatments are currently in use in pulmonary 
therapies. Research assessing muscular metabolism in CF could potentially benefit 
patients that meet adequate nutritional status through BMI yet remain at risk for low bone 
density due to consistent vitamin D inadequacy. It has also opened additional areas of 
possible clinical research that may add to the limited body of evidence available to CF 
clinicians. 
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APPENDICES 
 
Figure 1 Intervention timeline Patients with Cystic Fibrosis admitted for acute illness 
will be screened, randomized into two groups and monitored via blood samples for up to 
72 hours. 
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Figure 2. Flow diagram of participant enrollment. Subjects with Cystic Fibrosis (n 
=37) were screened for participation in the study. Seventeen subjects were enrolled and 
randomly assigned to receive either a powder or an oil vehicle of vitamin D3. One subject 
did not complete the intervention and one subject was excluded due to inadequate sample 
collection. 
 
37 
 
 
 
Table 1.  Participant Demographics 
DEMOGRAPHIC 
Powder  
(n=8,  ±SE) 
Oil  
(n=9,  ±SE) p-value* 
Age (yrs) 27.7 ± 2.3 25.7 ±2.0 0.77* 
Gender (%female) 62.5 33.3 0.35** 
Ethnicity (% white) 71.0 100.0 
Smoking 0 0 1.0 
BMI (kg/m2)+ 20.3 ± 1.1 21.1 ± 1.0 0.62* 
Enzymes (%) 87.5 87.5 1.0** 
Vitamin D supplements (%) 14.0 50.0 
Vitamin D Intake (IU) 262.2 292.0 0.81 
HBA1C (%) 7.98 ± 2.2 5.9 ±0 .17 1.0** 
Serum 25(OH)D3 (ng/mL) 22.6 ± 5.0 18.6 ± 3.3 0.50# 
Serum Cholecalciferol (ng/dL) 4.1 ±1.2 6 ± 2.3 0.29** 
FEV % in 1 sec 63.4 ± 10.0 55.8 ± 8.8 0.58* 
*Oneway ANOVA 
**Fisher’s Exact 2‐Tailed 
*ANOVA >F 
# Oneway ANOVA T‐test 
+Assumed equal variance    
 
 
 
 
 
Table 2. Serum Cholecalciferol by hour        
Group 
0 hour 
(ng/dL)* 
12 hours 
(ng/dL)* 
24 hours 
(ng/dL)* 
48 hours 
(ng/dL)* Pgroup Ptime 
Pgro
up*ti
me
Powder 4.62 ± 
9.40 E 
144.32± 
9.40 A 
107.0 ± 
9.40 B 
60.23± 10.80 
C,D 
0.071 <0.0001 0.00
01 
Oil 6.0± 
7.66 E 
80.0± 
7.66 B,C,D 
93.7 ± 7.66 
B,C 
60.05±8.32 D    
* Time points not associated by the same letter are significantly different,  p<.05 
Least Squares Means 
Two-way Mixed Model Repeated Measures ANOVA 
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Figure 3 Cholecalciferol, least squares means, N=15 Serum cholecalciferol increased 
over 48hrs in both the oil and the powder groups. The group-by-time interaction was 
statistically significant (Pgroup*time<0.0001) in the powder group. 
 
 
Figure 4 Mean AUC 
The AUC for serum cholecalciferol was also higher in the powder group compared to the 
oil group (3256.5±285.5 vs 2393.73±233.1, p = 0.036). 
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Table 3.  Serum  25-Hydroxyvitamin D3 (25(OH)D3) by hour 
  
0 hours 
(ng/mL)* 
 12 hours 
(ng/mL)* 
24 hours 
(ng/mL)* 
48 hours 
(ng/mL)* Pgroup Ptime Pgroup*time 
Powder 
24 
±4.3 
29.3   
±4.2 
31.3 
 ±4.2 
27.3             
±4.4 0.300 0.0062 0.347 
Oil 
18.6 
±3.4 
20.7  
±3.5 
22.9 
±3.4 
25.6 
±3.6 
*Serum 25(OH)D by time and group (LS mean +/- SEM).     
* Time points not associated by the same letter are 
significantly different,  p<.05 
 
 
 
 
 
 
Figure 5 Changes in Plasma 25-Hydroxyvitamin D Over Time, N=15 
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